

# MOST PRESCRIBED

**Hemangeol**<sup>®</sup>  
(propranolol hydrochloride)  
oral solution 4.28 mg/mL

HEMANGEOL IS  
THE MOST  
PRESCRIBED  
INFANTILE  
HEMANGIOMA  
TREATMENT  
IN AMERICA\*.

\*Details in footnote



SCAN  
TO LEARN  
MORE



HEM-2024-015

HEMANGEOL<sup>®</sup> (propranolol hydrochloride) oral solution is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. \*Most Prescribed claim based on data from Symphony Health, an ICON plc Company, IDV<sup>®</sup>, April 1, 2023 to April 1, 2024. HEMANGEOL<sup>®</sup>(propranolol hydrochloride) is contraindicated in the following conditions: ·Premature infants with corrected age <5 weeks; ·Infants weighing less than 2 kg; ·Known hypersensitivity to propranolol or any of the excipients; ·Asthma or history of bronchospasm; ·Heart rate < 80 beats per minute, greater than first degree heart block, or decompensated heart failure; ·Blood pressure < 50/30 mmHg; ·Pheochromocytoma. **WARNINGS AND PRECAUTIONS-** HEMANGEOL prevents the response of endogenous catecholamines to correct hypoglycemia and masks the adrenergic warning signs of hypoglycemia, particularly tachycardia, palpitations, and sweating.